AMGNAmgenFinished
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Melanoma
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Mar 2025, none posted yet
Counts until it's fixed
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score12
Score over time
- Stage
- Phase 3
- Patients
- 256 (final count)
- Started
- Jul 26, 2023
- Main results expected
- Mar 26, 2025
- Fully finished
- Oct 31, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Area Under the Serum Concentration-time Curve from Time Zero to 28 Days (AUC0-28d)
Measured over: Day 1 (Postdose) through Day 28
Area Under the Serum Concentration-time Curve Over the Dosing Interval at Steady State (AUCtau_SS)
Measured over: Week 17 through Week 21
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-03-26, no fading
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05907122 · record last updated 2026-03-27 · checked 2026-11-09 15:47 UTC